Source:http://linkedlifedata.com/resource/pubmed/id/16598519
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2006-4-6
|
| pubmed:abstractText |
Nicotinic acetylcholine receptors mediate the parasympathetic autonomic control of cardiac function. Aim of this study was the assessment of cardiac nicotinic acetylcholine receptor distribution with a novel (alpha4beta2) nicotinic acetylcholine receptor PET ligand (2-deoxy-2- [18F]fluoro-D-glucose-A85380) in humans. Five healthy volunteers without cardiac disease and six patients with either Parkinson's disease or multiple system atrophy without additional overt cardiac disease were evaluated with 2-deoxy-2-[18F]fluoro-D-glucose-A85380 PET-imaging to assess the cardiac parasympathetic innervation and the putative impact of both disorders. 2-deoxy-2- [18F]fluoro-D-glucose-A85380 whole body PET-scans were performed on a Siemens PET/CT biograph(TM) 75.4 min +/- 6.7 after i.v. injection of 371.2 +/- 58.1 MBq. Average count rate density of left ventricle ROI's and a standard ROI in the right lung were measured within three consecutive slices of 10.0 mm thickness. Heart-to-lung ratios were calculated in each volunteer and patient. Tracer uptake in the left ventricle could be measured in all of the five volunteers and the six patients. Heart-to-lung ratios in the volunteer group were not different from patients suffering from Parkinson's disease or MSA (3.2 +/- 0.5 vs 3.2 +/- 0.8 and 2.96+/-0.7, mean +/- SD), respectively. Human cardiac nicotinic acetylcholine receptors can be visualized and measured by 2-deoxy-2- [18F]fluoro-D-glucose-A85380 PET scans both in cardiac-healthy subjects and patients suffering from Parkinson's disease or multiple system atrophy. The heart- as well as the lung-tracer uptake was almost constant throughout all subjects leading to a good target-to-background ratio. These first results suggest no impact of either PD or MSA on cardiac nicotinic acetylcholine receptors.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
1861-0684
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
95
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
105-9
|
| pubmed:dateRevised |
2009-11-3
|
| pubmed:meshHeading |
pubmed-meshheading:16598519-Aged,
pubmed-meshheading:16598519-Feasibility Studies,
pubmed-meshheading:16598519-Female,
pubmed-meshheading:16598519-Fluorodeoxyglucose F18,
pubmed-meshheading:16598519-Heart,
pubmed-meshheading:16598519-Heart Ventricles,
pubmed-meshheading:16598519-Humans,
pubmed-meshheading:16598519-Male,
pubmed-meshheading:16598519-Middle Aged,
pubmed-meshheading:16598519-Multiple System Atrophy,
pubmed-meshheading:16598519-Myocardium,
pubmed-meshheading:16598519-Parkinson Disease,
pubmed-meshheading:16598519-Positron-Emission Tomography,
pubmed-meshheading:16598519-Radiopharmaceuticals,
pubmed-meshheading:16598519-Receptors, Nicotinic
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Feasibility of 2-deoxy-2-[18F]fluoro-D-glucose- A85380-PET for imaging of human cardiac nicotinic acetylcholine receptors in vivo.
|
| pubmed:affiliation |
University of Bonn, Department of Nuclear Medicine, Sigmund-Freud-Str. 25, 53105 Bonn, Germany. jan.bucerius@ukb.uni-bonn.de
|
| pubmed:publicationType |
Journal Article
|